Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selective...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xinxin, Zhou, Zhuan, Kang, Rui, Tang, Daolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629117/
https://www.ncbi.nlm.nih.gov/pubmed/36338145
http://dx.doi.org/10.1080/2162402X.2022.2141978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629117/
https://www.ncbi.nlm.nih.gov/pubmed/36338145
http://dx.doi.org/10.1080/2162402X.2022.2141978

Ejemplares similares